Ivosidenib
CAS 1448347-49-6 4 FDA-DMF suppliersSmall Molecule
Overview
Ivosidenib is a selective inhibitor of the isocitrate dehydrogenase 1 (IDH1) enzyme, which is used in the treatment of cancers with IDH1 mutations. It disrupts the production of oncometabolite 2-hydroxyglutarate, thereby inhibiting tumor growth.
Patent & exclusivity (US)
Per the FDA Orange Book (1 approved US product), the latest listed US patent on Ivosidenib expires 6 Jun 2039 and exclusivity 23 Oct 2030. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
OncologyHematology
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.